Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases

Med Hypotheses. 2005;64(1):120-3. doi: 10.1016/j.mehy.2004.03.047.


Several lines of evidence show that cyclin-dependent kinases (CDKs) contribute to neurodegenerative disorders such as Alzheimer's and Parkinson's diseases, and amyotrophic lateral sclerosis. Given their role in the neuronal apoptosis, the inhibition of CDKs by specific drugs such as flavopiridol may be a valid therapeutic approach. Expression of CDKs was observed in rodent models of excitotoxicity and stroke, and CDK inhibitors showed neuroprotective effects. Flavopiridol may provide significant improvement in neurodegenerative diseases in humans.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Apoptosis / drug effects*
  • Clinical Trials as Topic
  • Cyclin-Dependent Kinases / antagonists & inhibitors*
  • Cyclin-Dependent Kinases / metabolism*
  • Flavoproteins / administration & dosage*
  • Humans
  • Models, Neurological*
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / metabolism*
  • Neurons / drug effects
  • Neurons / metabolism*
  • Neuroprotective Agents / administration & dosage


  • Antineoplastic Agents
  • Flavoproteins
  • Neuroprotective Agents
  • Cyclin-Dependent Kinases